AERPIO PHARMACEUTICALS INC's ticker is ARPO and the CUSIP is 00810B105. A total of 43 filers reported holding AERPIO PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $8,778,000 | +31.0% | 5,193,946 | 0.0% | 0.09% | +41.3% |
| Q1 2021 | $6,700,000 | +31.6% | 5,193,946 | 0.0% | 0.06% | +40.0% |
| Q4 2020 | $5,090,000 | -34.7% | 5,193,946 | 0.0% | 0.04% | -54.1% |
| Q3 2020 | $7,791,000 | +20.0% | 5,193,946 | 0.0% | 0.10% | +7.7% |
| Q2 2020 | $6,492,000 | +127.3% | 5,193,946 | 0.0% | 0.09% | +89.6% |
| Q1 2020 | $2,856,000 | -11.8% | 5,193,946 | 0.0% | 0.05% | +4.3% |
| Q4 2019 | $3,238,000 | -8.3% | 5,193,946 | 0.0% | 0.05% | -31.3% |
| Q3 2019 | $3,531,000 | -25.3% | 5,193,946 | 0.0% | 0.07% | -8.2% |
| Q2 2019 | $4,726,000 | +1.0% | 5,193,946 | 0.0% | 0.07% | +1.4% |
| Q1 2019 | $4,680,000 | -47.0% | 5,193,946 | 0.0% | 0.07% | -55.8% |
| Q4 2018 | $8,830,000 | -45.0% | 5,193,946 | 0.0% | 0.16% | -15.5% |
| Q3 2018 | $16,049,000 | -25.5% | 5,193,946 | 0.0% | 0.19% | -24.9% |
| Q2 2018 | $21,555,000 | – | 5,193,946 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 5,621,835 | $9,501,000 | 5.16% |
| ABG Innovation Capital Partners III GP Ltd | 400,000 | $676,000 | 2.26% |
| Ikarian Capital, LLC | 1,676,093 | $2,832,000 | 0.23% |
| Avoro Capital Advisors LLC | 4,500,000 | $7,605,000 | 0.13% |
| Parkman Healthcare Partners LLC | 353,957 | $598,000 | 0.13% |
| Orbimed Advisors | 5,193,946 | $8,778,000 | 0.09% |
| RA Capital Management | 2,693,309 | $4,552,000 | 0.07% |
| Atom Investors LP | 79,996 | $135,000 | 0.02% |
| NEVILLE RODIE & SHAW INC | 100,000 | $169,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 208,674 | $353,000 | 0.01% |